Ferriprox Deferiprone

SAME ESTABLISHED SAFETY PROFILE

The Ferriprox safety profile has been established in 70+ studies worldwide.

 

NEW FERRIPROX® 1000 MG TABLETS HAVE THE SAME
ESTABLISHED SAFETY PROFILE AS THE 500 MG TABLETS

Ferriprox has 18+ years of worldwide post-marketing experience (6+ in the US) and over 90,000 patient-years of use.4

 

AGRANULOCYTOSIS/NEUTROPENIA

  • In clinical trials of 642 Ferriprox-treated patients:
    • Agranulocytosis occurred in 1.7% of patients
    • Neutropenia occurred in 6.2% of patients
  • Fatal agranulocytosis can occur with Ferriprox use. Ferriprox can also cause neutropenia, which may foreshadow agranulocytosis.
 
Most common adverse reactions occurring in >5% of patients treated with Ferriprox in clinical trials1
Adverse reaction % Subjects (n=642)
Nausea 13
Abdominal pain/discomfort 10
Vomiting 10
Arthralgia 10
Alanine aminotransferase increase 7
Neutrophil count decrease†† 7
 

References:

  • ‡ Chromaturia (reddish/brown discoloration of the urine) is a result of the excretion of the iron in the urine.
  • 1. Ferriprox (deferiprone) Prescribing Information. ApoPharma USA, 2019.
  • 4. Data on file, ApoPharma.